Oncocyte Corporation - Common Shares, No Par Value (OCX)
CUSIP: 68235C107
Q3 2024 13F Holders as of 30 Sep 2024
- Type / Class
- Equity / Common Shares, No Par Value
- Shares outstanding
- 28,495,649
- Total 13F shares
- 59,353
- Share change
- -1,093,042
- Total reported value
- $169,156
- Price per share
- $2.85
- Number of holders
- 1
- Value change
- -$3,224,887
- Number of buys
- 1
- Number of sells
- 1
Quarterly Holders Quick Answers
What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68235C107:
Top shareholders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BROADWOOD CAPITAL INC |
13F
|
Company |
15%
|
4,929,066
|
$14,540,745 | — | 30 Jun 2024 | |
| AWM Investment Company, Inc. |
13F
|
Company |
3.9%
|
1,097,175
|
$3,236,666 | — | 30 Jun 2024 | |
| PURA VIDA INVESTMENTS, LLC |
3/4/5
13F
|
10%+ Owner · Company |
1.5%
from 13F
|
16,591,052
mixed-class rows
|
$3,044,309 | — | 14 Apr 2023 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.76%
|
244,489
|
$721,243 | — | 30 Jun 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.29%
|
92,691
|
$273,499 | — | 30 Jun 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.24%
|
78,696
|
$232,153 | — | 30 Jun 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.23%
|
72,827
|
$214,840 | — | 30 Jun 2024 | |
| Defender Capital, LLC. |
13F
|
Company |
0.19%
|
55,220
|
$162,899 | — | 30 Jun 2024 | |
| John Peter Gutfreund |
3/4/5
|
Former Director |
—
mixed-class rows
|
760,000
mixed-class rows
|
$153,654 | — | 30 Jun 2023 | |
| Ronald Asbury Andrews |
3/4/5
|
Former CEO, Director |
—
mixed-class rows
|
633,212
mixed-class rows
|
$125,332 | — | 01 Dec 2022 | |
| Alfred D. Kingsley |
3/4/5
|
Director |
—
mixed-class rows
|
597,878
mixed-class rows
|
$109,143 | — | 23 Jun 2023 | |
| Gisela Paulsen |
3/4/5
|
Former President and COO |
—
class O/S missing
|
366,500
|
$78,761 | — | 16 Dec 2022 | |
| Li Yu |
3/4/5
|
VP Cntrllr/Prncpl Acctng Offcr |
—
mixed-class rows
|
41,872
mixed-class rows
|
$76,536 | — | 18 May 2022 | |
| FNY Investment Advisers, LLC |
13F
|
Company |
0.07%
|
23,654
|
$69,000 | — | 30 Jun 2024 | |
| STATE STREET CORP |
13F
|
Company |
0.06%
|
19,554
|
$57,684 | — | 30 Jun 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.05%
|
17,346
|
$51,170 | — | 30 Jun 2024 | |
| Ross Douglas T. |
3/4/5
|
Former CSO |
—
class O/S missing
|
234,114
|
$50,311 | — | 21 Dec 2022 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.03%
|
10,418
|
$30,733 | — | 30 Jun 2024 | |
| Cavan M. Redmond |
3/4/5
|
Director |
—
class O/S missing
|
120,863
|
$25,973 | — | 24 Jun 2022 | |
| Mitchell S. Levine |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
174,580
mixed-class rows
|
$18,713 | — | 15 Mar 2022 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
3,069
|
$9,054 | — | 30 Jun 2024 | |
| Jennifer Levin Carter |
3/4/5
|
Director |
—
mixed-class rows
|
75,500
mixed-class rows
|
$6,554 | — | 15 Aug 2022 | |
| Melinda Griffith |
3/4/5
|
Director |
—
mixed-class rows
|
75,000
mixed-class rows
|
$6,447 | — | 15 Aug 2022 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,127
|
$3,324 | — | 30 Jun 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
835
|
$2,464 | — | 30 Jun 2024 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0%
|
500
|
$1,475 | — | 30 Jun 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
416
|
$1,228 | — | 30 Jun 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
154
|
$454 | — | 30 Jun 2024 | |
| Riggs Asset Managment Co. Inc. |
13F
|
Company |
0%
|
50
|
$148 | — | 30 Jun 2024 | |
| Piscataqua Savings Bank |
13F
|
Company |
0%
|
25
|
$73 | — | 30 Jun 2024 | |
| Coppell Advisory Solutions LLC |
13F
|
Company |
0%
|
10
|
$30 | — | 30 Jun 2024 | |
| ALBION FINANCIAL GROUP /UT |
13F
|
Company |
0%
|
7
|
$21 | — | 30 Jun 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
1
|
$3 | — | 30 Jun 2024 | |
| Anish M. John |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
121,381
|
— | — | 24 Feb 2023 | |
| Padmavathi Sundar |
3/4/5
|
Chief Commercial Officer |
—
class O/S missing
|
87,500
|
— | — | 15 Mar 2022 |
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q3 2024
As of 30 Sep 2024,
Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by
1 institutional
shareholder
that filed Form 13F with the SEC.
Together, they reported ownership of
59,353 shares.
The largest 1 holders included
Defender Capital, LLC..
This page lists
1
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2024 vs Q2 2024 Across Filers
Q2 2024 holders
2
Q3 2024 holders
1
Holder diff
-1
| Investor | Q2 2024 Shares | Q3 2024 Shares | Share Diff | Share Chg % | Q2 2024 Value $ | Q3 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.